Cargando…
The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience
Autores principales: | Rush, Cassandra, Faulk, Kelly E., Bradley, Zanette Kanani, Turner, Aubree, Krumins, Maija, Greenhawt, Matthew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648374/ https://www.ncbi.nlm.nih.gov/pubmed/34883262 http://dx.doi.org/10.1016/j.jaip.2021.11.025 |
Ejemplares similares
-
Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase
por: Faschinger, Alexander M., et al.
Publicado: (2019) -
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
por: Heo, Young-A., et al.
Publicado: (2019) -
Repeated prescription of known identified drugs with a history of drug allergy
por: Wiwanitkit, Viroj
Publicado: (2011) -
Pegaspargase Induced Hypertriglyceridemia Resulting in Severe Fatal Pancreatitis
por: Vyas, Neil, et al.
Publicado: (2015) -
Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase
por: Yu-tong, Zhang, et al.
Publicado: (2014)